N-ethyl-N-methyl-6-(trimethylstannyl)pyridine-3-sulfonamide → 6'-amino-N-ethyl-N-methyl-5'-(7-oxo-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)-[2,3'-bipyridine]-5-sulfonamide

HRID 2091577Notes

Reaction equation

HRID 2091577 reaction equation
[CH2:1]([N:3]([CH3:17])[S:4]([C:7]1[CH:8]=[N:9][C:10]([Sn](C)(C)C)=[CH:11][CH:12]=1)(=[O:6])=[O:5])[CH3:2].[NH2:18][C:19]1[C:24]([C:25]2[S:34][C:28]3[C:29](=[O:33])[NH:30][CH2:31][CH2:32][C:27]=3[CH:26]=2)=[CH:23][C:22](Br)=[CH:21][N:20]=1>>[NH2:18][C:19]1[N:20]=[CH:21][C:22]([C:10]2[CH:11]=[CH:12][C:7]([S:4]([N:3]([CH2:1][CH3:2])[CH3:17])(=[O:6])=[O:5])=[CH:8][N:9]=2)=[CH:23][C:24]=1[C:25]1[S:34][C:28]2[C:29](=[O:33])[NH:30][CH2:31][CH2:32][C:27]=2[CH:26]=1

Participants

3

Procedure

The final step of general method D was applied to N-ethyl-N-methyl-6-(trimethylstannyl)pyridine-3-sulfonamide (233 mg, 0.6 mmol) and 2-(2-amino-5-bromopyridin-3-yl)-5,6-dihydrothieno[2,3-c]pyridin-7(4H)-one (194 mg, 0.6 mmol) to give 6′-amino-N-ethyl-N-methyl-5′-(7-oxo-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)-[2,3′-bipyridine]-5-sulfonamide as a yellow solid (140 mg, 0.31 mmol, 53% yield) after purification by reverse phase preparatory HPLC. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.91 (d, J=2.0 Hz, 1H), 8.85 (d, J=2.3 Hz, 1H), 8.26 (d, J=2.3 Hz, 1H), 8.10-8.19 (m, 2H), 7.73 (br. s, 1H), 7.33 (s, 1H), 6.62 (s, 2H), 3.44-3.50 (m, 2H), 3.09 (s, 2H), 2.86 (t, J=1.0 Hz, 1H), 2.72 (s, 3H), 1.01-1.09 (m, 3H); MS (EI) m/z=444.5 [M+1]+.

Sources & evidence

ORD record
ord-d3f6c310ffe6420ba258d953f583d449
Source dataset
uspto-grants-2013_05
Patent number
US08440652B2

Reaction notes

Loading…